Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.
- SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update.
- Nurix and Sanofi extended their ongoing research program for STAT6 (signal transducer and activator of transcription 6).
- Nurix retains its option to co-develop and co-promote future products in the United States under programs for which Nurix has exercised its option.
- Nurix presented new clinical data for NX-5948 at the American Association for Cancer Research (AACR) 2024 Annual Meeting.